Results 71 to 80 of about 12,625 (176)

Severe HCoV‐OC43 Pneumonia in a 25‐Year‐Old Woman Following Allogeneic Hematopoietic Stem Cell Transplantation

The Clinical Respiratory Journal, Volume 20, Issue 5, May 2026.
This case reports a 25‐year‐old allo‐HCT recipient with severe HCoV‐OC43 pneumonia who responded well to off‐label nirmatrelvir/ritonavir. It is the first such report that show the drug may benefit immunocompromised patients with this infection, though further studies are needed to confirm efficacy.
Mingzhou Zhang, Ting Tang, Mingxia Zheng, Menglin Luo, Zhi Xu, Guansong Wang   +5 more
wiley   +1 more source

2‐Phenylquinolines Exhibit Anti‐Severe Acute Respiratory Syndrome Coronavirus‐2 Activity Through the Nonstructural Protein 13 Helicase Inhibition

ChemMedChem, Volume 21, Issue 7, 14 April 2026.
A SAR study led to the identification of new 2‐phenylquinoline‐based derivatives that exhibit anti‐Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) activity by acting as ATP‐competitive inhibitors of nonstructural protein 13 (nsp13) helicase.
Giada Cernicchi, Maria Giulia Nizi, Roberta Emmolo, Leentje Persoons, Manon Laporte, Dirk Jochmans, Isabella Romeo, Giacomo Pepe, Ciro Milite, Pietro Campiglia, Jacopo Spezzini, Alma Martelli, Simone Brogi, Francesca Esposito, Tommaso Felicetti, Serena Massari, Giuseppe Manfroni, Stefano Sabatini, Gianluca Sbardella, Stefano Alcaro, Johan Neyts, Angela Corona, Enzo Tramontano, Steven De Jonghe, Oriana Tabarrini   +24 more
wiley   +1 more source

Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

, 2023
Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir
Jiménez-Lorenzo, M.-J., Varricchio, G., Delia, M., Di Blasi, R., Bergantim, R., Wolf, D., Tragiannidis, A., López-García, A., Papa, M.V., Salmanton-García, J., Guidetti, A., Samarkos, M., Ommen, H.-B., Garcia-Vidal, C., Mikulska, M., Glenthøj, A., Pagano, L., Dragonetti, G., Lahmer, T., Nunes Rodrigues, R., Gavriilaki, E., Fernández, N., Dávila-Valls, J., Nucci, M., García-Poutón, N., Ribera-Santa Susana, J.-M., Soto-Silva, A., Itri, F., Buquicchio, C., Finizio, O., Falces-Romero, I., Bonanni, M., Petzer, V., Marchesi, F., Piukovics, K., Eggerer, M., Pinczés, L.I., Yahya, A., Arellano, E., Serrano, L., Gräfe, S.K., De Jonge, N., Merelli, M., Nordlander, A., Méndez, G.-A., Zompi, S., Zambrotta, G.P.M., Van Praet, J., Biernat, M.M., Bilgin, Y.M., Cabirta, A., Espigado, I., Batinić, J., Del Principe, M.I., Busca, A., Jaksic, O., Cattaneo, C., Shan Kho, C., Meers, S., Hersby, D.S., Cornely, O.A., De Ramón, C., De Kort, E., Emarah, Z., Sili, U., Van Doesum, J., Verga, L., Criscuolo, M., Prattes, J., Cordini, G., Labrador, J., Aujayeb, A., Chi, L.Y.A., Marques de Almeida, J., Çolak, G.M., El-Ashwah, S., EPICOVIDEHA registry, Cordoba, R., Rahimli, L., Plantefeve, G., Coppola, N., Fianchi, L., Giordano, A., Jiménez, M., Dargenio, M., Prezioso, L., Stojanoski, Z., Martín-Pérez, S., Schönlein, M., Hernández-Rivas, J.-Á., Aiello, T.F., Blennow, O., Danion, F., Cuccaro, A., Ammatuna, E., González-López, T.J., Marchetti, M., Meletiadis, J., Machado, M., Hoenigl, M., Fracchiolla, N.S., Valković, T., Tascini, C., Anastasopoulou, A.N., Colović, N., Gomes da Silva, M., Vena, A., Duléry, R., Sacchi, M.V., Weinbergerová, B., Erben, N., Prin, R., Ormazabal-Vélez, I., Hassan, N., Besson, C., Farina, F., Stamouli, M.   +116 more
core  

Structure‐ and Ligand‐Based Discovery of Novel 3‐Chymotrypsin‐Like Protease Nonpeptidomimetic Hits

ChemMedChem, Volume 21, Issue 7, 14 April 2026.
A multistep virtual screening cascade, integrating shape‐based, ensemble docking, and quantitative structure–activity relationship (QSAR) models, was employed to screen 1.5 million compounds. This funnel identified a novel 3‐chymotrypsin‐like protease (3CLpro) inhibitor, LabMol‐499, which was experimentally validated using a Förster Resonance Energy ...
Sabrina Silva‐Mendonça, Donald Seanego, Christopher Jurisch, Melina Mottin, Flávia Nader Motta, Beatriz S. A. Rodrigues, Gilberto S. M. Junior, Alexandra Maria dos Santos Carvalho, Fábio Muniz de Oliveira, Sunniva Sigurdardóttir, Per Sunnerhagen, Izabela Marques Dourado Bastos, Richard Gessner, Kelly Chibale, Carolina Horta Andrade   +14 more
wiley   +1 more source

COVID‐19 Antiviral Treatment: Examining Knowledge, Access, Trust in Sources of Information and Willingness to Use Among Essential Workers: A Cross‐Sectional Survey of Cohort Participants

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Despite evidence of effectiveness, oral antivirals for COVID‐19 are underused, with significant variation across populations. This study examines COVID‐19 treatment awareness, knowledge, access, trusted sources, and willingness to use among diverse essential workers in Tennessee during May 18, 2023–June 1, 2024.
Jenae Sanders, Jade James‐Gist, Melisa M. Shah, Nathan Graff, Olivia Almendares, Tiffany Israel, Yuwei Zhu, Bryan Blette, Sarah Hamid, Hope King, H. Keipp Talbot, Carlos G. Grijalva, Melissa Briggs‐Hagen   +12 more
wiley   +1 more source

A case report of drug interaction between co-packaged nirmatrelvir-ritonavir and tacrolimus causing hyponatremia in a lung transplant recipient

Journal of Cardiothoracic Surgery
Background Coronavirus disease 2019 (COVID-19) infection in lung transplant recipients can be lethal owing to the use of immunosuppressants. Antiviral agents may be administered to these patients.
Chien-Ming Lo, Wei-Hsun Chen, Meng-Yun Tsai, Hung-I Lu, Yu-Hsin Hsiao, Kai-Hao Chuang, Yu Chen, Hsuan-Feng Wu, Kuo-Tung Huang, Yi-Hsi Wang   +9 more
doaj   +1 more source

Post nirmatrelvir/ritonavir erythema multiforme in a patient with coronavirus disease infection

, 2023
Erythema multiforme (EM), an immune-mediated skin condition, can occur after infection or following the use of medications. In this study, we describe a patient who developed EM after nirmatrelvir/ritonavir administration.
José Carlos Jucá Pompeu Filho (16017914), Luiz Eduardo Garcia Galvão (16017917), José Wagner Leonel Tavares-Júnior (10367885)   +2 more
core   +1 more source

Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12–17 years following SARS-CoV-2 Omicron infection: A target trial emulation

Nature Communications
Currently there is a lack of randomized trial data examining the use of the antiviral nirmatrelvir/ritonavir in paediatric patients with SARS-CoV-2 infection.
Carlos K. H. Wong, Kristy T. K. Lau, Ivan C. H. Au, Sophelia H. S. Chan, Eric H. Y. Lau, Benjamin J. Cowling, Gabriel M. Leung   +6 more
doaj   +1 more source

Incidence of severe COVID‐19 in patients with chronic lymphocytic leukaemia or indolent B‐cell non‐Hodgkin lymphoma who received vaccination and pre‐exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi

British Journal of Haematology, Volume 208, Issue 5, Page 1816-1820, May 2026.
Gian Matteo Rigolin, Stefano Soddu, Riccardo Dondolin, Anna Maria Frustaci, Ilaria Scortechini, Francesca Romana Mauro, Francesco Angotzi, Marina Motta, Lydia Scarfò, Andrea Mengarelli, Annamaria Giordano, Sara Martinelli, Caterina Patti, Paolo Sportoletti, Alessandro Sanna, Nilla Maschio, Rossella Riccioni, Clara Virginia Viganò, Agostino Tafuri, Alfonso Piciocchi, Paola Fazi, Stefano Luminari, Andrés J. M. Ferreri, Guido Gini, Paolo Ghia, Antonio Cuneo   +25 more
wiley   +1 more source

Comparative effectiveness of combination therapy with nirmatrelvir-ritonavir and molnupiravir versus monotherapy with molnupiravir or nirmatrelvir-ritonavir in hospitalized COVID-19 patients:A target trial emulation study [PDF]

Background Molnupiravir and nirmatrelvir-ritonavir have demonstrated efficacy in reducing hospitalization and mortality among unvaccinated, high-risk COVID-19 outpatients. However, their impact on hospitalized adults remains unclear.
Boyuan Wang, Wang, Boyuan, Wong, Ian Chi Kei, Wing Ming Chu, Chan, Esther Wai Yin, Kwok Yung Yuen, Eric Yuk Fai Wan, Ian Chi Kei Wong, Yuen, Kwok Yung, Choi, Ming Hong, Esther Wai Yin Chan, Chu, Wing Ming, Ivan Fan Ngai Hung, Xu, Yahui, Yahui Xu, Ming Hong Choi, Wan, Eric Yuk Fai, Anthony Raymond Tam, Hung, Ivan Fan Ngai, Tam, Anthony Raymond   +19 more
core   +1 more source